Cantabria Labs will promote and sponsor MIT in its biomedical innovation programmes. The Massachusetts Institute of Technology (MIT) is a Cambridge-based university founded in 1861 to become a benchmark for innovation in the world. Cantabria Labs has a strong young entrepreneurial spirit in its DNA that has led it to support the MIT’s direction by investing in biomedicine as a future for researching various medical specialties. “We will be supporting and integrating our commitment to medicine in the future with even more effort through biomedical research. “MIT for us is a field of projects that we think tomorrow can change the future and improve people’s quality of life,” says Cantabria Labs’s Innovation and Business Development Director Susana Rodriguez. Last July, the signing of an agreement providing financial support for 3 years between Industrial Farmacéutica Cantabria and the Massachusetts Institute of Technology was completed. Research and innovation are key words in the Cantabria Labs vocabulary, which today has more than 44 brands of drugs, cosmetics and nutraceuticals marketed in more than 80 countries. According to the CEO of Cantabria Labs, the company has set itself the goal of increasing turnover to 300 million over a five-year period. Cantabria Labs will soon begin construction of its new manufacturing facility in the Cantabrian city of La Concha, planning to invest 20 million Euros thee. This manufacturing plant, which will replace the current one in Santander, will be built in two years and will allow a ten-fold increase in the Group’s current production capacity.